RecruitingNCT06754345
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment
100 participants
Start Date
May 30, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) for the evaluation of PD-L1 expression in primary and/or metastatic tumors, compared with histopathological results.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with pd-l1 and tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 90 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06754345
Related Trials
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
NCT066907361 location
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
NCT066909571 location
FAPI PET/CT in Various FAP-Related Disease Patients
NCT066880711 location
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
NCT067256931 location
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
NCT061082321 location